Pharma Partnering EU 2026: Biotech BD&L Trends to Watch

Key Takeaways

• Pharma Partnering EU Summit 2026 will convene in Basel, Switzerland, focusing on business development and licensing.
• The summit will feature pre-arranged one-to-one meetings, company presentations, and panel discussions to foster collaborations.
• Discussions are expected to highlight recent clinical data in oncology, immunology, and rare diseases, reflecting current partnering trends.
• Keep an eye on key players like Boehringer Ingelheim, Zai Lab, AbbVie, and Eli Lilly, who have been active in recent partnering deals.

The Pharma Partnering EU Summit 2026 is set to take place on May 20–21, 2026, in Basel, Switzerland. This event will concentrate on business development and licensing (BD&L), providing a platform for global pharmaceutical and biotech leaders to connect, explore potential collaborations, and drive innovation in the industry.

Pharma Partnering EU Summit 2026 is designed to facilitate strategic alliances, licensing agreements, and investments within the pharmaceutical and biotech sectors. The summit will feature pre-arranged one-to-one meetings, allowing senior executives to engage in focused discussions. Company presentations will showcase assets and technologies, while panel discussions will address industry trends, emerging therapies, and global strategies. While specific late-breaking abstracts are not yet available, the agenda promises valuable insights into the evolving landscape of pharmaceutical partnerships.

Partnering Themes

Discussions at the summit will likely address recent positive clinical data readouts, particularly in high-interest areas such as oncology, immunology, and rare diseases. Recent partnering deals in Q1 2026 indicate a strong focus on oncology and the integration of artificial intelligence (AI) in drug development. Companies such as Boehringer Ingelheim, Zai Lab, AbbVie, and Eli Lilly have been actively involved in these deals, signaling key areas of interest for potential partnerships.

For example, Cosmo Pharma announced positive Phase III data for clascoterone in androgenetic alopecia (AGA). Eli Lilly's Jaypirca (pirtobrutinib) extended progression-free survival (PFS) in previously treated CLL/SLL. GSK reported positive data for a B7-H4-targeted ADC. IDEAYA/Servier had positive data for darovasertib in metastatic uveal melanoma (mUM). Revolution Medicines announced positive Phase III data for rasonrasib in oncology. Spyre Therapeutics reported positive Phase II data for SPY001 in ulcerative colitis. SynOx Therapeutics had positive Phase III data for emactuzumab in tenosynovial giant cell tumor (TGCT). AbbVie's Elahere (mirvetuximab soravtansine) succeeded in a Phase II PSOC trial. Genmab presented updated Phase I/II data for rinatabart sesutacan, an epcoritamab-related ADC. These clinical advancements are expected to drive partnering discussions.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for biotech. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Companies to Watch

Several companies have been particularly active in recent partnering deals and should be closely watched at the event. These include Boehringer Ingelheim, Zai Lab, AbbVie, Eli Lilly, Regeneron, and GSK. Presentations from companies showcasing their assets and technologies will be a key component of the summit. Additionally, insights from leaders at companies like Astellas Pharma Europe, Bayer, and NTC Pharma will provide valuable perspectives on the evolution of pharmaceutical partnerships.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market & Investor Implications

The Pharma Partnering EU Summit serves as a barometer for investment and partnering trends in the pharmaceutical industry. The focus on oncology, AI, and innovative therapies reflects the current priorities of investors and pharmaceutical companies. Positive clinical data readouts and strategic collaborations announced at the summit can significantly impact market valuations and investor confidence.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for biotech pricing, access, and launch sequencing.

What to Watch Next

As the event approaches, keep an eye out for the release of the detailed agenda, including specific company presentations and panel discussions. Monitoring news and press releases from participating companies will provide insights into potential deals and collaborations that may emerge from the summit. Also of note are other EU-focused partnering events in 2026, including Outsourcing in Clinical Trials (OCT) Europe and Digi-Tech Pharma & AI.

Frequently Asked Questions

References

1. Pharma Partnering EU Summit. PlastikMedia.
2. Pharma Phriday, April 17, 2026 Edition. Pharmatell.
3. Pharma Partnering Summit US 2026. Evertise.
4. PHARMAP 2026: From Vendors to Strategic Partners. Pharmaphorum.
5. Pharma Partnering Summit.
6. Pharma Partnering EU Summit. PlastikMedia.

Related coverage

• EMEA 2026 Life Sciences Report: Key Market Shifts for Pharma BD and Investors
• Maersk Europe Market Update June 2026: Key Changes for Pharma Supply Chains
• Regulatory round-up: 2 February 2026 – EMA opinions, FDA approvals, and what they mean for pharma